Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease

Inflammatory Bowel Diseases

Volumn 15, Issue 6, 2009, Pages 803-806

  Alkhouri, Naim ^a   Hupertz, Vera ^a   Mahajan, Lori ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISONE; TACROLIMUS; TRIAMCINOLONE;

ADOLESCENT; ADULT; CASE REPORT; CLINICAL FEATURE; COLON RESECTION; COLONOSCOPY; COLOSTOMY; CROHN DISEASE; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GASTRITIS; GRANULOMA; HEMICOLECTOMY; HUMAN; ILEOSTOMY; LETTER; MUSCLE CRAMP; PERISTOMAL PYODERMA GANGRENOSUM; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; STOMA; TREATMENT DURATION; TREATMENT RESPONSE; WOUND CARE;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLOSTOMY; CROHN DISEASE; FEMALE; HUMANS; PYODERMA GANGRENOSUM;

EID: 67650249527     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20748     Document Type: Letter

References (24)

1. Brunsting L, Goeckerman W, O'Leary P. Pyoderma (ecthyma) gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Dermatol. 1930;22: 655-680.
2. Reguiai Z, Grange F. The role of anti-tumor necrosis factor-alpha therapy in pyoderma gangrenosum associated with inflammatory bowel disease. Am J Clin Dermatol. 2007;8: 67-77.
3. Tjandra JJ, Hughes LE. Parastomal pyoderma gangrenosum in inflammatory bowel disease. Dis Colon Rectum. 1994;37:938-942.
4. Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr. 2002;34:558-560.
5. Cairns BA, Herbst CA, Sartor BR, et al. Peristomal pyoderma gangrenosum and inflammatory bowel disease. Arch Surg. 1994;129: 769-772.
6. Kiran RP, O'Brien-Ermlich B, Achkar JP, et al. Management of peristomal pyoderma gangrenosum. Dis Colon Rectum. 2005;48:1397-1403.
7. Callen JP. Pyoderma gangrenosum. Lancet. 1998;351:581-585.
8. McGarity WC, Robertson DB, McKeown PP, et al. Pyoderma gangrenosum at the parastomal site in patients with Crohn's disease. Arch Surg. 1984;119:1186-1188.
9. Keltz M, Lebwohl M, Bishop S. Peristomal pyoderma gangrenosum. J Am Acad Dermatol. 1992;27:360-364.
10. Sheldon DG, Sawchuk LL, Kozarek RA, et al. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg. 2000;135:564-568; discussion 568-569.
11. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA. 2000;284:1546-1548.
12. Reichrath J, Bens G, Bonowitz A, et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53:273-283.
13. Lyon CC, Smith AJ, Beck MH, et al. Parastomal pyoderma gangrenosum: clinical features and management. J Am Acad Dermatol. 2000;42:992-1002.
14. Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol. 2002;3: 149-158.
15. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505-509.
16. Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821-1826.
17. Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol. 2006;54:S128-134.
18. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
19. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130:323-333; quiz 591.
20. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239.
21. Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005;152:1059-1061.
22. Fonder MA, Cummins DL, Ehst BD, et al. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds. 2006; 5:e8.
23. Heffernan MP, Anadkat MJ, Smith DI. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol. 2007;143:306-308.
24. Pomerantz RG, Husni ME, Mody E, et al. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol. 2007;157:1274-1275.